Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma

  • Home
  • 2020
  • April
  • 20
  • Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma

Original Source

On April 20, 2020

Post navigation

Previous PostBristol Myers Squibb Announces Virtual 2020 Annual Meeting of Shareholders
Next PostReblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes

Related Post

May 25, 2022
  • Business News

Boeing, NASA Complete First Starliner Space Station Flight Test

May 25, 2022
  • Business News

Northrop Grumman Australia Announces Tech Showcase Winners

May 25, 2022
  • Business News

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219